Company intelligence / Profile preview

Alzprotect

Loos/Lille area, Hauts-de-France, Francealzprotect.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Alzprotect has completed a Phase IIa clinical trial of its lead candidate Ezeprogind/AZP2006 in Progressive Supranuclear Palsy, showing promising safety and initial efficacy signals. The molecule was well tolerated and showed first signs of efficacy, leading to an extension of the trial and positive regulatory feedback from both EMA and FDA. A pivotal Phase IIb/III study is being prepared in Europe and the US. AZP2006 has orphan drug designation for PSP in both regions. The company also aims to expand into Alzheimer’s disease with this asset.

Therapeutic areas: Neurology
Modalities: small molecules
Industry: Biotech

Drug pipeline

1 asset

Ezeprogind

Beyond the preview

Go deeper on Alzprotect.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alzprotect.

Explore the full profile